| abstract |
The present invention comprises a bispecific monovalent diabody comprising two polypeptide chains and having at least one binding site specific for the epitope of gpA33 and one binding site specific for the epitope of CD3 (ie , “GpA33 × CD3 bispecific monovalent diabody”). The present invention also relates to a bispecific monovalent diabody comprising an immunoglobulin Fc domain (“bispecific monovalent Fc diabody”), comprising three polypeptide chains, And a diabody possessing at least one binding site specific for the epitope of gpA33 and one binding site specific for the epitope of CD3 (ie, “gpA33 × CD3 bispecific monovalent Fc diabody”) And The bispecific monovalent diabody and bispecific monovalent Fc diabody of the present invention can bind to gpA33 and CD3 simultaneously. The present invention is directed to a pharmaceutical composition comprising the bispecific monovalent diabody or the bispecific monovalent Fc diabody. The invention further relates to methods of using the above bispecific antibodies in the treatment of cancer and other diseases and conditions. [Selection] Figure 3A |